Sumitomo Mitsui Trust Group Trims Boston Scientific Stake

Institutional investor reduces position in medical device company

Apr. 12, 2026 at 11:05am

Got story updates? Submit your updates here. ›

An extreme close-up of the complex, interlocking metal components of a medical device manufacturing machine, conveying the industrial might and technical sophistication behind Boston Scientific's products.An institutional investor's reduced stake in Boston Scientific highlights the volatility and competitive pressures facing the medical device industry.Marlborough Today

Sumitomo Mitsui Trust Group Inc. reduced its stake in shares of Boston Scientific Corporation by 3.3% during the fourth quarter, according to a recent 13F filing. The firm owned 3,457,461 shares of the medical equipment provider's stock, valued at $329,669,000 at the end of the reporting period.

Why it matters

This reduction in Sumitomo Mitsui Trust Group's Boston Scientific holdings signals a shift in the institutional investor's outlook on the medical device company, which could impact the stock price and trading activity.

The details

Sumitomo Mitsui Trust Group sold 119,283 shares of Boston Scientific during the fourth quarter. The firm now owns approximately 0.23% of Boston Scientific's outstanding shares. The medical equipment provider's stock has seen volatility in recent months due to broader market conditions and concerns over the regulatory environment.

  • Sumitomo Mitsui Trust Group reduced its stake in the fourth quarter of 2025.
  • The 13F filing reporting this change in position was published on April 12, 2026.

The players

Sumitomo Mitsui Trust Group Inc.

A major Japanese financial services group and institutional investor.

Boston Scientific Corporation

A global medical device company that develops and markets a broad range of products used in less-invasive medical procedures.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Sumitomo Mitsui Trust Group's position in Boston Scientific reflects broader uncertainty in the medical device sector, as investors weigh factors like regulatory changes, market competition, and economic conditions.